|

NKX019 Clinical Trials

2 actively recruiting trials across 2 locations

Also known as: NKX019 infusion

Pipeline

Phase 1: 1Phase 1/2: 1

Top Sponsors

  • Nkarta, Inc.1
  • Columbia University1

Indications

  • Lupus2
  • Lupus Nephritis1
  • Primary Membranous Nephropathy1
  • Systemic Lupus Erythematosus1

Little Rock, Arkansas1 trial

A Phase 1/2 Study of NKX019 in Subjects With Autoimmune Disease (Ntrust-1)

Nkarta Investigational Site

Phase 1/2

New York, New York1 trial

A Study of NKX019, a CD19 CAR NK Cell Therapy, in Subjects With Systemic Lupus Erythematosus

Columbia University Irving Medical Center

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.